IL289912A - Second generation seneca valley virus oncolytic therapy: compositions and methods thereof - Google Patents
Second generation seneca valley virus oncolytic therapy: compositions and methods thereofInfo
- Publication number
- IL289912A IL289912A IL289912A IL28991222A IL289912A IL 289912 A IL289912 A IL 289912A IL 289912 A IL289912 A IL 289912A IL 28991222 A IL28991222 A IL 28991222A IL 289912 A IL289912 A IL 289912A
- Authority
- IL
- Israel
- Prior art keywords
- generation
- methods
- virus preparations
- valley virus
- seneca valley
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876191P | 2019-07-19 | 2019-07-19 | |
| PCT/US2020/042795 WO2021016194A1 (en) | 2019-07-19 | 2020-07-20 | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL289912A true IL289912A (en) | 2022-03-01 |
Family
ID=74193871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289912A IL289912A (en) | 2019-07-19 | 2022-01-17 | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12502414B2 (https=) |
| EP (1) | EP3999087A4 (https=) |
| JP (1) | JP2022541234A (https=) |
| KR (1) | KR20220035931A (https=) |
| CN (1) | CN115038456A (https=) |
| AU (1) | AU2020315800A1 (https=) |
| BR (1) | BR112022000928A2 (https=) |
| CA (1) | CA3147640A1 (https=) |
| IL (1) | IL289912A (https=) |
| WO (1) | WO2021016194A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096201A1 (en) | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| BR112022000928A2 (pt) | 2019-07-19 | 2022-03-08 | Seneca Therapeutics Inc | Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma |
| CN116059260A (zh) * | 2023-03-07 | 2023-05-05 | 华南农业大学 | Sva病毒在制备肿瘤防治药物中的应用及抗肿瘤组合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| US20030129215A1 (en) | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
| MXPA06003318A (es) | 2003-09-26 | 2006-06-08 | Novartis Ag | Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad. |
| US7638318B2 (en) | 2003-09-26 | 2009-12-29 | Norvartis Ag | Seneca Valley virus based compositions and methods for treating disease |
| ITRM20060337A1 (it) | 2006-06-27 | 2007-12-28 | Biosoot Srl | Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici |
| WO2008112891A2 (en) | 2007-03-13 | 2008-09-18 | Neotropix, Inc. | Monoclonal antibody that recognizes a seneca valley virus (svv) cellular receptor and uses thereof |
| US20100183633A1 (en) | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
| US20120100109A1 (en) | 2010-10-26 | 2012-04-26 | Xiaoliu Zhang | Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors |
| EP2637692A4 (en) | 2010-11-12 | 2014-09-10 | Scott & White Healthcare | ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8 |
| SG192673A1 (en) | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| GB201217892D0 (en) | 2012-10-05 | 2012-11-21 | Virttu Biolog Ltd | Treatment of cancer |
| WO2014089124A1 (en) | 2012-12-03 | 2014-06-12 | Cenexys, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| RU2696312C2 (ru) | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| WO2017096201A1 (en) * | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| MY203926A (en) | 2016-02-24 | 2024-07-24 | Childrens Hospital Of Eastern Ontario Res Institute Inc | Smc combination therapy for the treatment of cancer |
| WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| KR102056066B1 (ko) | 2016-12-09 | 2019-12-17 | 진메디신 주식회사 | 세포외 기질 분해 인자를 발현하는 재조합 아데노바이러스를 포함하는 항암용 조성물 |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| CN109022374B (zh) | 2018-08-16 | 2021-05-14 | 华中农业大学 | 一种塞内卡谷病毒重组质粒、重组病毒及构建方法 |
| MX2021001883A (es) | 2018-08-16 | 2021-07-15 | Musc Found For Res Dev | Virus recombinantes del mixoma y usos de los mismos. |
| US20220000921A1 (en) | 2018-11-20 | 2022-01-06 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified Cell Expressing Therapeutic Agent and Uses thereof |
| JP2022516318A (ja) | 2019-01-04 | 2022-02-25 | オンコラス， インコーポレイテッド | カプセル化ポリヌクレオチド及び使用方法 |
| US20220119478A1 (en) | 2019-01-15 | 2022-04-21 | Caerus Therapeutics, Corp. | Advanced chimeric antigen receptor vectors for targeting solid tumors |
| WO2020210711A1 (en) | 2019-04-11 | 2020-10-15 | Seneca Therapeutics, Inc. | Compositions and methods of using seneca valley virus (svv) for treating cancer |
| BR112022000928A2 (pt) | 2019-07-19 | 2022-03-08 | Seneca Therapeutics Inc | Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma |
| CN111154806A (zh) | 2020-01-08 | 2020-05-15 | 深圳普菲科生命科技有限公司 | 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用 |
| CA3207860A1 (en) | 2021-01-11 | 2022-07-14 | Seneca Therapeutics, Inc. | Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor |
-
2020
- 2020-07-20 BR BR112022000928A patent/BR112022000928A2/pt not_active IP Right Cessation
- 2020-07-20 JP JP2022502812A patent/JP2022541234A/ja active Pending
- 2020-07-20 AU AU2020315800A patent/AU2020315800A1/en active Pending
- 2020-07-20 CN CN202080065213.6A patent/CN115038456A/zh active Pending
- 2020-07-20 KR KR1020227005152A patent/KR20220035931A/ko not_active Ceased
- 2020-07-20 US US17/626,879 patent/US12502414B2/en active Active
- 2020-07-20 WO PCT/US2020/042795 patent/WO2021016194A1/en not_active Ceased
- 2020-07-20 EP EP20843259.1A patent/EP3999087A4/en active Pending
- 2020-07-20 CA CA3147640A patent/CA3147640A1/en active Pending
-
2022
- 2022-01-17 IL IL289912A patent/IL289912A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022000928A2 (pt) | 2022-03-08 |
| CA3147640A1 (en) | 2021-01-28 |
| US12502414B2 (en) | 2025-12-23 |
| KR20220035931A (ko) | 2022-03-22 |
| EP3999087A1 (en) | 2022-05-25 |
| EP3999087A4 (en) | 2023-08-23 |
| AU2020315800A1 (en) | 2022-03-03 |
| WO2021016194A1 (en) | 2021-01-28 |
| US20220249584A1 (en) | 2022-08-11 |
| CN115038456A (zh) | 2022-09-09 |
| JP2022541234A (ja) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289912A (en) | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof | |
| IL279897A (en) | Fusosome compositions and uses thereof | |
| IL280566A (en) | Systems and methods for affecting cardiac contractility and/or relaxation | |
| IL268891A (en) | Polyploid adeno-associated virus vectors and methods of making and using the same | |
| EP3494123A4 (en) | ARNI AGENT AGAINST HEPATITIS B INFECTION | |
| EP3658165A4 (en) | ONCOLYTIC VIRAL VECTORS AND THEIR USES | |
| IL280559A (en) | Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof | |
| PL3807297T3 (pl) | Syntetyczne wątrobowo-tropowe kapsydy wirusa związanego z adenowirusem i ich zastosowania | |
| EP3810634A4 (en) | Mosaic influenza virus hemagglutinin polypeptides and uses thereof | |
| IL263818A (en) | Anti-zika virus antibodies and methods of use | |
| IL280317A (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| EP3731850A4 (en) | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES | |
| IL280183A (en) | Highly purified and/or modified fucan compositions for the treatment of fibrous adhesions | |
| IL284044A (en) | Antibodies that neutralize hepatitis b virus and uses thereof | |
| EP3577132A4 (en) | ONCOLYTIC VIRUS THERAPY | |
| MA54085A (fr) | Signatures d'interféron de type i et méthodes d'utilisation | |
| EP4204751A4 (en) | FREEZE-DRYING SYSTEMS AND PROCESSES | |
| DK3768305T5 (da) | Modificerede, onkolytiske adenovira | |
| HUE055343T2 (hu) | A hepatitis delta vírusfertõzés kezelése interferon lambdával | |
| EP3334833A4 (en) | RECOMBINANT TURKEY HERPESVIRUS VACCINES AND USES THEREOF | |
| EP3518947C0 (en) | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | |
| EP3840773A4 (en) | Treatment of hepatitis delta virus infection with interferon lambda | |
| IL314393A (en) | Human papillomavirus vaccines and uses of the same | |
| EP4069197C0 (en) | CO-AMORPHOUS FORMS OF BETA-LACTOGLOBULIN AND A DRUG SUBSTANCE | |
| EP3810164A4 (en) | ANTIGENIC DISGUISED ONCOLYTIC VIRUSES |